<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Ansuvimab (United States: Available via manufacturer expanded access or public health distribution): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Ansuvimab (United States: Available via manufacturer expanded access or public health distribution): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Ansuvimab (United States: Available via manufacturer expanded access or public health distribution): Drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_pediatric" data-topicid="130482" href="/d/html/130482.html" rel="external">see "Ansuvimab (United States: Available via manufacturer expanded access or public health distribution): Pediatric drug information"</a> and <a class="drug drug_patient" data-topicid="130493" href="/d/html/130493.html" rel="external">see "Ansuvimab (United States: Available via manufacturer expanded access or public health distribution): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F55347356"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antiviral Agent;</li>
<li>
                        Monoclonal Antibody</li></ul></div>
<div class="block doa drugH1Div" id="F55455735"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="798ca1a5-e33d-4c53-95af-e74c4890bb50">
<i>Zaire ebolavirus</i> infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:0em;display:inline">
<b>
<i>Zaire ebolavirus</i> infection: IV:</b> 50 mg/kg as a single dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31774950']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31774950'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F55455737"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F55455738"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied).</p></div>
<div class="block doe drugH1Div" id="F55455736"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F55424775"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="130482" href="/d/html/130482.html" rel="external">see "Ansuvimab (United States: Available via manufacturer expanded access or public health distribution): Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="798ca1a5-e33d-4c53-95af-e74c4890bb50">
<i>Zaire ebolavirus</i> infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Zaire ebolavirus</i> infection:</b> Infants, Children, and Adolescents: IV: 50 mg/kg as a single dose.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F55424776"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block dohp drugH1Div" id="F55424777"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block arsc drugH1Div" id="F55808431"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Infusion-related reactions</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Infusion-related reactions </b>commonly occurred with ansuvimab administration during clinical trials. Signs and symptoms may include <b>fever</b>,<b> tachycardia</b>, <b>diarrhea</b>,<b> vomiting</b>, <b>hypotension</b>,<b> tachypnea</b>, <b>chills</b>, or <b>hypoxia</b>. May require slowing of the infusion rate or treatment interruption; treatment discontinuation may be required for severe or life-threatening <b>hypersensitivity reactions</b>.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Not clearly established; clinicians should consider the impact of the underlying <i>Zaire ebolavirus </i>infection on the development of these symptoms.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Rapid; during or immediately following the infusion</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Rate of infusion</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F55355026"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Increased serum potassium (15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase (12%), increased serum aspartate aminotransferase (13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine (27%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (≥17%)<span class="lexi-table-link-container"> (<a aria-label="Fever table link" class="lexi-table-link" data-table-id="lexi-content-fever" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-fever')">table 1</a>)</span><span class="table-link" style="display:none;">Fever</span>, infusion related reaction (29%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Fever" frame="border" id="lexi-content-fever" rules="all">
<caption style="text-align:center;">
<b>Ansuvimab: Adverse Reaction: Fever</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Ansuvimab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Various)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Ansuvimab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Comparator)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">17%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">58%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50 mg/kg as a single infusion</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">173</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">168</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Reflects reactions that occurred during or immediately after infusion</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypotension (8%)<span class="lexi-table-link-container"> (<a aria-label="Hypotension table link" class="lexi-table-link" data-table-id="lexi-content-hypotension" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-hypotension')">table 2</a>)</span><span class="table-link" style="display:none;">Hypotension</span>, tachycardia (9%)<span class="lexi-table-link-container"> (<a aria-label="Tachycardia table link" class="lexi-table-link" data-table-id="lexi-content-tachycardia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-tachycardia')">table 3</a>)</span><span class="table-link" style="display:none;">Tachycardia</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Hypotension" frame="border" id="lexi-content-hypotension" rules="all">
<caption style="text-align:center;">
<b>Ansuvimab: Adverse Reaction: Hypotension</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Ansuvimab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Various)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Ansuvimab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Comparator)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">31%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50 mg/kg as a single infusion</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">173</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">168</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Reflects reactions that occurred during or immediately after infusion</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Tachycardia" frame="border" id="lexi-content-tachycardia" rules="all">
<caption style="text-align:center;">
<b>Ansuvimab: Adverse Reaction: Tachycardia</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Ansuvimab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Various)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Ansuvimab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Comparator)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">32%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50 mg/kg as a single infusion</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">173</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">168</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Reflects reactions that occurred during or immediately after infusion</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased serum potassium (6%), decreased serum sodium (7%), increased serum sodium (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (≥9%)<span class="lexi-table-link-container"> (<a aria-label="Diarrhea table link" class="lexi-table-link" data-table-id="lexi-content-diarrhea" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-diarrhea')">table 4</a>)</span><span class="table-link" style="display:none;">Diarrhea</span>, vomiting (≥8%)<span class="lexi-table-link-container"> (<a aria-label="Vomiting table link" class="lexi-table-link" data-table-id="lexi-content-vomiting" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-vomiting')">table 5</a>)</span><span class="table-link" style="display:none;">Vomiting</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Diarrhea" frame="border" id="lexi-content-diarrhea" rules="all">
<caption style="text-align:center;">
<b>Ansuvimab: Adverse Reaction: Diarrhea</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Ansuvimab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Various)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Ansuvimab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Comparator)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">18%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50 mg/kg as a single infusion</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">173</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">168</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Reflects reactions that occurred during or immediately after infusion</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Vomiting" frame="border" id="lexi-content-vomiting" rules="all">
<caption style="text-align:center;">
<b>Ansuvimab: Adverse Reaction: Vomiting</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Ansuvimab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Various)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Ansuvimab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Comparator)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">23%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50 mg/kg as a single infusion</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">173</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">168</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Reflects reactions that occurred during or immediately after infusion</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Chills (5%)<span class="lexi-table-link-container"> (<a aria-label="Chills table link" class="lexi-table-link" data-table-id="lexi-content-chills" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-chills')">table 6</a>)</span><span class="table-link" style="display:none;">Chills</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Chills" frame="border" id="lexi-content-chills" rules="all">
<caption style="text-align:center;">
<b>Ansuvimab: Adverse Reaction: Chills</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Ansuvimab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Various)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Ansuvimab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Comparator)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">33%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50 mg/kg as a single infusion</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">173</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">168</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Reflects reactions that occurred during or immediately after infusion</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Hypoxia (3%)<span class="lexi-table-link-container"> (<a aria-label="Hypoxia table link" class="lexi-table-link" data-table-id="lexi-content-hypoxia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-hypoxia')">table 7</a>)</span><span class="table-link" style="display:none;">Hypoxia</span>, tachypnea (6%)<span class="lexi-table-link-container"> (<a aria-label="Tachypnea table link" class="lexi-table-link" data-table-id="lexi-content-tachypnea" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-tachypnea')">table 8</a>)</span><span class="table-link" style="display:none;">Tachypnea</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Hypoxia" frame="border" id="lexi-content-hypoxia" rules="all">
<caption style="text-align:center;">
<b>Ansuvimab: Adverse Reaction: Hypoxia</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Ansuvimab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Various)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Ansuvimab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Comparator)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50 mg/kg as a single infusion</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">173</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">168</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Reflects reactions that occurred during or immediately after infusion</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Tachypnea" frame="border" id="lexi-content-tachypnea" rules="all">
<caption style="text-align:center;">
<b>Ansuvimab: Adverse Reaction: Tachypnea</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Ansuvimab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Various)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Ansuvimab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Comparator)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">28%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50 mg/kg as a single infusion</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">173</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">168</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Reflects reactions that occurred during or immediately after infusion</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Hypersensitivity: Hypersensitivity reaction</p></div>
<div class="block coi drugH1Div" id="F55347350"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">There are no contraindications listed in the manufacturer's labeling.</p></div>
<div class="block war drugH1Div" id="F55424767"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p></div>
<div class="block prod-avail drugH1Div" id="F55347346"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Ebanga: FDA approved December 2020. Product will not be commercially available; will only be distributed for a public health emergency in the US.</p></div>
<div class="block adm drugH1Div" id="F55455739"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>IV:</b> If refrigerated, allow diluted infusion solution to come to room temperature prior to administration. Administer IV over 60 minutes with a 1.2 micron in-line filter extension set; may be infused via central or peripheral catheter. Do not administer IV push or bolus. May slow or interrupt infusion for signs of infusion-associated events or other adverse events. After infusion is complete, flush the line with ≥25 mL of diluent.</p></div>
<div class="block admp drugH1Div" id="F55424800"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: IV: Must be reconstituted and further diluted prior to administration. If diluted solution is refrigerated following preparation, allow solution to come to room temperature prior to administration. Administer over 60 minutes using an in-line 1.2 micron filter extension set. Do <b>NOT</b> administer as an IV push or bolus. Flush line with compatible diluent following completion of infusion to ensure entire dose is administered; flush volume varies based on administration method (eg, syringe vs IV infusion bag). Slow or interrupt infusion if the patient develops any signs of infusion-associated events (eg, hypotension, chills, fever elevation) or other adverse events; if severe or life-threatening hypersensitivity reactions occur, immediately discontinue infusion and provide emergency care.</p>
<p style="text-indent:-2em;margin-left:4em;">Syringe administration: Flush line with 2 to 5 mL compatible diluent; do not exceed total infusion volume.</p>
<p style="text-indent:-2em;margin-left:4em;">IV bag administration: Flush line with ≥25 mL compatible diluent.</p></div>
<div class="block use drugH1Div" id="F55347349"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Zaire ebolavirus</i> infection:</b> Treatment of infection caused by <i>Z. ebolavirus</i> in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for <i>Z. ebolavirus</i> infection.</p>
<p style="text-indent:-2em;margin-left:4em;">Limitations of use: Efficacy has not been established for other species of the <i>Ebolavirus </i>and <i>Marburgvirus </i>genera.</p></div>
<div class="block cyt drugH1Div" id="F55367136"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F55367133"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Ebola Zaire Vaccine (Live): Ebola-Directed Monoclonal Antibodies may diminish the therapeutic effect of Ebola Zaire Vaccine (Live).  Management: Wait several months (3 to 6 months, and up to 11 months) after use of Ebola-directed antibodies before administering the live Ebola Zaire vaccine. Repeat vaccination may be required if antibody therapy and vaccination cannot be adequately separated.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Efgartigimod Alfa: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rozanolixizumab: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F55455730"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Animal reproduction studies have not been conducted. Ansuvimab is a humanized monoclonal antibody (IgG<sub>1</sub>) and would be expected to cross the placenta. Placental transfer of human IgG is dependent upon the IgG subclass, maternal serum concentrations, newborn birth weight, and gestational age, generally increasing as pregnancy progresses. The lowest exposure would be expected during the period of organogenesis (Palmeira 2012; Pentsuk 2009).</p>
<p style="text-indent:0em;margin-top:2em;">Outcome information following maternal use of ansuvimab during pregnancy is limited (Mulangu 2019; Ottoni 2020).</p>
<p style="text-indent:0em;margin-top:2em;">Following maternal infection, the Ebola virus can be detected in maternal body fluids and transmitted to the fetus. Maternal Ebola infection carries a high rate of mortality for both the fetus and the mother. Maternal Ebola virus infection typically results in miscarriage, stillbirth, and maternal and/or neonatal death (Olgun 2018). Treatment with ansuvimab should not be withheld due to pregnancy.</p>
<p style="text-indent:0em;margin-top:2em;">Pregnant health care providers should not care for patients with Ebola virus disease (CDC 2018).</p></div>
<div class="block brc drugH1Div" id="F55455731"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if ansuvimab is present in breast milk; however, ansuvimab is a humanized monoclonal antibody (IgG<sub>1</sub>) and maternal IgG is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Following maternal infection, the Ebola virus can be detected in body fluids, including breast milk. Infected mothers can transmit the Ebola virus to their infant via breast milk (Olgun 2018; WHO 2020).</p>
<p style="text-indent:-2em;margin-left:2em;">The Centers for Disease Control and Prevention recommends mothers with Ebola virus infection completely avoid breastfeeding to decrease the potential transmission to their infants (CDC 2018). The World Health Organization recommends lactating patients with acute Ebola virus infection be separated from their breastfeeding child and milk substitutes be provided. Patients who have recovered from Ebola virus disease should have 2 consecutive negative Ebola virus breast milk tests by RT-PCR separated by 24 hours before feeding with breast milk is resumed (WHO 2020).</p></div>
<div class="block mop drugH1Div" id="F55455741"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor for hypersensitivity and infusion-related reactions (fever, chills, and hypotension) during and after the infusion.</p></div>
<div class="block pha drugH1Div" id="F55455734"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Ansuvimab is a recombinant human IgG1κ monoclonal antibody that binds to the glycan cap and inner chalice of the <i>Z. ebolavirus </i>(EBOV) glycoprotein 1 (GP1) subunit, blocking binding of EBOV GP1 to the Neiman Pick cell receptor 1 in host cells, inhibiting virus entry.</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics.</i> 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ansuvimab-united-states-available-via-manufacturer-expanded-access-or-public-health-distribution-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.1">
<a name="CDC.1"></a>Centers for Disease Control (CDC). Centers for Disease Control and Prevention guidance for screening and caring for pregnant women with Ebola virus disease for healthcare providers in U.S. hospitals. <a href="https://www.cdc.gov/vhf/ebola/clinicians/evd/pregnant-women.html" target="_blank">https://www.cdc.gov/vhf/ebola/clinicians/evd/pregnant-women.html</a>. Updated May 30, 2018. Accessed January 7, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product.<i> MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ansuvimab-united-states-available-via-manufacturer-expanded-access-or-public-health-distribution-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Ebanga (ansuvimab) [prescribing information]. Miami, FL: Ridgeback Biotherapeutics LP; May 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313. doi:10.1034/j.1600-0536.2002.4705104.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ansuvimab-united-states-available-via-manufacturer-expanded-access-or-public-health-distribution-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ansuvimab-united-states-available-via-manufacturer-expanded-access-or-public-health-distribution-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31774950">
<a name="31774950"></a>Mulangu S, Dodd LE, Davey RT Jr, et al; PALM Consortium Study Team. A randomized, controlled trial of ebola virus disease therapeutics. <i>N Engl J Med</i>. 2019;381(24):2293-2303. doi:10.1056/NEJMoa1910993<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ansuvimab-united-states-available-via-manufacturer-expanded-access-or-public-health-distribution-drug-information/abstract-text/31774950/pubmed" id="31774950" target="_blank">31774950</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29384053">
<a name="29384053"></a>Olgun NS. Viral infections in pregnancy: a focus on ebola virus. <i>Curr Pharm Des</i>. 2018;24(9):993-998. doi:10.2174/1381612824666180130121946<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ansuvimab-united-states-available-via-manufacturer-expanded-access-or-public-health-distribution-drug-information/abstract-text/29384053/pubmed" id="29384053" target="_blank">29384053</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33217357">
<a name="33217357"></a>Ottoni MP, Ricciardone JD, Nadimpalli A, et al. Ebola-negative neonates born to Ebola-infected mothers after monoclonal antibody therapy: a case series. <i>Lancet Child Adolesc Health</i>. 2020;4(12):884-888. doi:10.1016/S2352-4642(20)30278-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ansuvimab-united-states-available-via-manufacturer-expanded-access-or-public-health-distribution-drug-information/abstract-text/33217357/pubmed" id="33217357" target="_blank">33217357</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22235228">
<a name="22235228"></a>Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental transfer in healthy and pathological pregnancies. <i>Clin Dev</i>
<i>Immunol</i>. 2012;2012:985646. doi:10.1155/2012/985646<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ansuvimab-united-states-available-via-manufacturer-expanded-access-or-public-health-distribution-drug-information/abstract-text/22235228/pubmed" id="22235228" target="_blank">22235228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19626656">
<a name="19626656"></a>Pentsuk N, van der Laan JW. An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. <i>Birth Defects Res B Dev Reprod Toxicol.</i> 2009;86(4):328-344. doi:10.1002/bdrb.20201<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ansuvimab-united-states-available-via-manufacturer-expanded-access-or-public-health-distribution-drug-information/abstract-text/19626656/pubmed" id="19626656" target="_blank">19626656</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313. doi:10.1016/s0140-6736(95)90963-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ansuvimab-united-states-available-via-manufacturer-expanded-access-or-public-health-distribution-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32091684">
<a name="32091684"></a>World Health Organization (WHO). Guidelines for the management of pregnant and breastfeeding women in the context of Ebola virus disease. World Health Organization; February 2020. https://apps.who.int/iris/bitstream/handle/10665/330851/9789240001381-eng.pdf?ua=1. Accessed January 28, 2021.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ansuvimab-united-states-available-via-manufacturer-expanded-access-or-public-health-distribution-drug-information/abstract-text/32091684/pubmed" id="32091684" target="_blank">32091684</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 130467 Version 29.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
